Experimental study on the inhibitive effect of Fuzheng-yiliu Decoction on ovarian cancer and its mechanism

GE Rong; SHENG Qing-song; YANG Yin

PDF(1200 KB)

Anhui Journal of Preventive Medicine ›› 2017, Vol. 23 ›› Issue (6) : 385-389.

Experimental study on the inhibitive effect of Fuzheng-yiliu Decoction on ovarian cancer and its mechanism

GE Rong¹, SHENG Qing-song², YANG Yin¹

Author information +

History +

Abstract

Objective To explore the inhibitive effects of Fuzheng-yiliu Decoction on ovarian cancer and its mechanism. Methods The tumor bearing models of human ovarian cancer were established in 40 nude mice, which were randomly divided into 4 groups: the control group, the large dosage group, the moderate dosage group and the small dosage group, and respectively received saline or Fuzheng-yiliu with different concentrations (30g/kg,20g/kg or10g/kg) by gavage administration for 3 weeks. After the tumor sizes were measured, the mice in each group were sacrificed with the tumor peeled and weighed. Cell cycles in the tumor tissue were determined by flow cytometry. The expression levels of PCNA and VEGF protein in the tumor tissue were determined by Western blotting. ELISA was used to determine the serum levels of IL-2 and INF-γ. Results When compared to the control group, the tumor sizes and weight were all significantly decreased in the Fuzheng-yiliu Decoction groups(P<0.05), and the inhibitive effect was more intensive with the dosage increased(P<0.01). More cells at G1 stage with fewer cells at S stage and G2 stage were detected in the tumor tissue with the dosage increased(P<0.01).The protein expression of PCNA and VEGF in the tumor tissue were significantly down-regulated, while the serum levels of IL-2 and INF-γ were significantly up-regulated by Fuzheng-yiliu Decoction in a dosage-dependent model(P<0.01). Conclusion Fuzheng-yiliu Decoction can inhibit the growth of transplanted ovarian cancer in nude mice in a dosage-dependent model; the possible mechanism may lie in the cell-cycle regulation,the falling-regulation of PCNA and VEGF expression in tumor tissue,and the improvement of immune function.

Key words

Fuzheng-yiliu Decoction / Ovarian cancer / Inhibitive effect / Animal experiment / Experimental study

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

GE Rong, SHENG Qing-song, YANG Yin. Experimental study on the inhibitive effect of Fuzheng-yiliu Decoction on ovarian cancer and its mechanism[J]. Anhui Journal of Preventive Medicine. 2017, 23(6): 385-389

References

[1] Vandecaveye V, Dresen R, De Keyzer F. Novel imaging techniques in gynaecological cancer[J]. Curr Opin Oncol. 2017,29(5):335-342.
[2] El Bairi K, Amrani M, Kandhro AH, et al. Prediction of therapy response in ovarian cancer: Where are we now[J].Crit Rev Clin Lab Sci,2017,54(4):233-266.
[3] 沈爱云,严小萍,顾凌云. 扶正抑瘤汤对结直肠癌化疗后患者机体免疫影响的研究[J]. 现代中西医结合杂志,2015,24(27):2980-2982.
[4] 黄桂军,王华,陈朝宽,等.扶正抑瘤汤对晚期前列腺癌患者生存期和生活质量的影响[J].江苏中医药,2010,42(6):18-20.
[5] 黄军,孔祥应,汪琳,等.扶正抑瘤汤联合恩度治疗晚期非小细胞肺癌的疗效观察[J].现代中西医结合杂志,2015,24(9):955-957.
[6] 黄继汉, 黄晓晖, 陈志扬, 等. 药理试验中动物间和动物与人体间的等效剂量换算[J]. 中国临床药理学与治疗学,2004;9(9):1069-1072.
[7] 沈代条. 党参的药理作用和临床应用[J]. 临床合理用药杂志,2014,25(29):92-92.
[8] 孔祥应, 黄军, 汪琳, 等. 扶正抑瘤汤治疗晚期非小细胞肺癌患者化疗相关性疲乏的临床观察[J]. 北方药学,2016,13(6): 85-86.
[9] 管若男,范蕾,刘丽娟. TPh对肝癌细胞HepG-2细胞周期、凋亡及相关因子表达的影响[J]. 中国生化药物杂志,2017,2(37):15-19.
[10] 赵万忠,程凯,王晓红,等. 补骨脂素对乳腺癌耐药细胞株周期和细胞凋亡的影响[J]. 中华临床医师杂志(电子版),2016,(14):2111-2115.
[11] Strzalka W,Ziemienowicz A.Proliferating cell nuclear antigen(PCNA):a key factor in DNA replication and cell cycle regulation[J].Ann Bot,2011,107(7):1127-1140.
[12] 陈书尚,翁明芳,王水良,等. 补骨脂素对前列腺癌LNCap-AD细胞增殖的影响及其分子机制研究[J]. 中华细胞与干细胞杂志(电子版),2017; 7(4):219-223.
[13] 魏昕,杨举伦.Ki-67和PCNA表达与乳腺癌及乳腺癌化疗敏感性的关系[J].中国免疫学杂志,2014,11(30):1549-1551.
[14] 宋国智,李利敏.人脑胶质瘤中PCNA的表达及临床意义[J].脑与神经疾病,2012,20(2):133-136.
[15] Gu L,Smith S,Li C,et al.A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth [J]. PLoS One,2014,9(4):e94773.
[16] 郑华峰,陶晶,张斌,等. MiR-495通过下调PCNA抑制人血管内皮细胞增殖的作用研究[J]. 中国心血管病研究,2016,14(4): 374-379.
[17] Chen XL,Nam JO,Jean C,et al.VEGF-induced vascular permeability is mediated by FAK[J],Dev Cell,2012,22(1):146-57.
[18] YangⅪ ,Zhang Y,Hosaka K,et al.VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism an d serves as a marker of poor prognosis for cancer patients [J]. Proc Natl Acad Sci USA,2015,112(22):2900-2909.
[19] Yu L,Deng L,H J,et al.The prognostic value of vascular endothelial growth factor in ovarian cancer:a systematic review and meta-analysis[J].Gynecol Oncol,2013,128(2):391-396.
[20] Sallinen H,Heikura T,Koponen J,et al.Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer[J].BMC Cancer,2014,14(1):1-11.
[21] 单秀玲. 卵巢癌患者化疗前后血清CA125、IL-2和SIL-2R检测的临床应用[J].放射免疫学杂志. 2012,25(2):135-137.
[22] Rasooly R, Do P, Hernlem BJ. Interleukin 2 secretion by T cells for detection of biologically active staphylococcal enterotoxin type E[J]. J Food Prot,2017,9:1857-1862.
[23] Shadman M, Rajabian Z, Ajami A, et al. Frequency of γδ T cells and invariant natural killer T cells in helicobacter pylori-infected patients with peptic ulcer and gastric cancer[J]. Iran J Allergy Asthma Immunol,2015,14(5):493-501.